http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 27 Feb 2026 17:25:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Feb+23/26083776.html si-local-file:///var/storage/secattach/20260227/26083776.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Feb+23/26083776.html Fri, 27 Feb 2026 17:25:00 -0500 LYRA O.04855546 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Feb+23/26083776.html si-local-file:///var/storage/secattach/20260227/26083776.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Feb+23/26083776.html Fri, 27 Feb 2026 17:25:00 -0500 LYRA O.04855546 http://www.streetinsider.com/Corporate+News/NASDAQ+moves+to+delist+Lyra+Therapeutics+over+public+shell+concerns/25961712.html <p>Lyra Therapeutics Inc. (NASDAQ: LYRA) received a delisting determination from NASDAQ on February 2, 2026, according to a company statement based on a staff letter from the exchange's Listing Qualifications Department.</p><p>NASDAQ cited the company as a "public shell" under Listing Rule 5101, referencing Lyra's January 12, 2026 Form 8-K filing that disclosed the board's decision to suspend development of LYR-210, its lead product candidate. The filing also detailed a reduction in force that terminated nearly all employees, with the chief executive officer and chief financial officer converted from employees to consultants.</p><p>The exchange stated the company no longer maintains an operating http://www.streetinsider.com/Corporate+News/NASDAQ+moves+to+delist+Lyra+Therapeutics+over+public+shell+concerns/25961712.html Fri, 06 Feb 2026 16:14:58 -0500 LYRA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Feb+02/25961673.html si-local-file:///var/storage/secattach/20260206/25961673.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Feb+02/25961673.html Fri, 06 Feb 2026 16:12:00 -0500 LYRA O.04855546 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Feb+02/25961673.html si-local-file:///var/storage/secattach/20260206/25961673.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Feb+02/25961673.html Fri, 06 Feb 2026 16:12:00 -0500 LYRA O.04855546 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Lyra+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+Palasis+Maria/25900255.html si-local-file:///var/storage/secattach/20260127/25900255.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Lyra+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+Palasis+Maria/25900255.html Tue, 27 Jan 2026 15:39:00 -0500 LYRA O.04855546 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Lyra+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+Palasis+Maria/25900255.html si-local-file:///var/storage/secattach/20260127/25900255.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Lyra+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+Palasis+Maria/25900255.html Tue, 27 Jan 2026 15:39:00 -0500 LYRA O.04855546 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Lyra+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+SABBY+MANAGEMENT%2C+LLC/25869757.html si-local-file:///var/storage/secattach/20260120/25869757.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Lyra+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+SABBY+MANAGEMENT%2C+LLC/25869757.html Tue, 20 Jan 2026 19:18:00 -0500 LYRA O.04855546 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Lyra+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+SABBY+MANAGEMENT%2C+LLC/25869757.html si-local-file:///var/storage/secattach/20260120/25869757.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Lyra+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+SABBY+MANAGEMENT%2C+LLC/25869757.html Tue, 20 Jan 2026 19:18:00 -0500 LYRA O.04855546 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Jan+09/25834157.html si-local-file:///var/storage/secattach/20260112/25834157.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Jan+09/25834157.html Mon, 12 Jan 2026 07:30:00 -0500 LYRA O.04855546 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Jan+09/25834157.html si-local-file:///var/storage/secattach/20260112/25834157.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Jan+09/25834157.html Mon, 12 Jan 2026 07:30:00 -0500 LYRA O.04855546 http://www.streetinsider.com/Guidance/Lyra+Therapeutics+suspends+lead+drug+development%2C+cuts+workforce/25833968.html <p>Lyra Therapeutics Inc. (NASDAQ: LYRA) announced its board of directors decided to suspend development of LYR-210, the company's lead treatment candidate for chronic rhinosinusitis. The biotech company also implemented a workforce reduction affecting its remaining 28 employees and other cost-cutting measures to preserve capital.</p><p>The company retained Chief Executive Officer Maria Palasis and Chief Financial Officer Jason Cavalier as consultants to pursue strategic alternatives. Lyra has engaged SSG Capital Advisors to assist with this effort, according to a company statement.</p><p>"In connection with the Company's review of strategic options, which was announced in May 2024, the Board has concluded that it is http://www.streetinsider.com/Guidance/Lyra+Therapeutics+suspends+lead+drug+development%2C+cuts+workforce/25833968.html Mon, 12 Jan 2026 07:03:43 -0500 LYRA http://www.streetinsider.com/Corporate+News/Lyra+Therapeutics+suspends+lead+drug+development%2C+cuts+workforce/25833968.html <p>Lyra Therapeutics Inc. (NASDAQ: LYRA) announced its board of directors decided to suspend development of LYR-210, the company's lead treatment candidate for chronic rhinosinusitis. The biotech company also implemented a workforce reduction affecting its remaining 28 employees and other cost-cutting measures to preserve capital.</p><p>The company retained Chief Executive Officer Maria Palasis and Chief Financial Officer Jason Cavalier as consultants to pursue strategic alternatives. Lyra has engaged SSG Capital Advisors to assist with this effort, according to a company statement.</p><p>"In connection with the Company's review of strategic options, which was announced in May 2024, the Board has concluded that it is http://www.streetinsider.com/Corporate+News/Lyra+Therapeutics+suspends+lead+drug+development%2C+cuts+workforce/25833968.html Mon, 12 Jan 2026 07:03:43 -0500 LYRA http://www.streetinsider.com/Press+Releases/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html <p>WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis (CRS). The Company also announced a workforce reduction impacting its remaining 28 employees and other cost-saving actions to preserve capital. Maria Palasis, Ph.D., Chief Executive Officer, President and Chair of the Board, and Mr. Jason Cavalier, Chief Financial Officer and Treasurer, are each being retained as consultants to support the Company’s pursuit of strategic alternatives. http://www.streetinsider.com/Press+Releases/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html Mon, 12 Jan 2026 07:00:00 -0500 A.06822034 LYRA O.04855546 O.20026344 http://www.streetinsider.com/Press+Releases/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html <p>WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis (CRS). The Company also announced a workforce reduction impacting its remaining 28 employees and other cost-saving actions to preserve capital. Maria Palasis, Ph.D., Chief Executive Officer, President and Chair of the Board, and Mr. Jason Cavalier, Chief Financial Officer and Treasurer, are each being retained as consultants to support the Company’s pursuit of strategic alternatives. http://www.streetinsider.com/Press+Releases/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html Mon, 12 Jan 2026 07:00:00 -0500 A.06822034 LYRA O.04855546 O.20026344 http://www.streetinsider.com/Press+Releases/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html <p>WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis (CRS). The Company also announced a workforce reduction impacting its remaining 28 employees and other cost-saving actions to preserve capital. Maria Palasis, Ph.D., Chief Executive Officer, President and Chair of the Board, and Mr. Jason Cavalier, Chief Financial Officer and Treasurer, are each being retained as consultants to support the Company’s pursuit of strategic alternatives. http://www.streetinsider.com/Press+Releases/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html Mon, 12 Jan 2026 07:00:00 -0500 A.06822034 LYRA O.04855546 O.20026344 http://www.streetinsider.com/Press+Releases/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html <p>WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis (CRS). The Company also announced a workforce reduction impacting its remaining 28 employees and other cost-saving actions to preserve capital. Maria Palasis, Ph.D., Chief Executive Officer, President and Chair of the Board, and Mr. Jason Cavalier, Chief Financial Officer and Treasurer, are each being retained as consultants to support the Company’s pursuit of strategic alternatives. http://www.streetinsider.com/Press+Releases/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html Mon, 12 Jan 2026 07:00:00 -0500 A.06822034 LYRA O.04855546 O.20026344 http://www.streetinsider.com/Globe+Newswire/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html <p>WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis (CRS). The Company also announced a workforce reduction impacting its remaining 28 employees and other cost-saving actions to preserve capital. Maria Palasis, Ph.D., Chief Executive Officer, President and Chair of the Board, and Mr. Jason Cavalier, Chief Financial Officer and Treasurer, are each being retained as consultants to support the Company’s pursuit of strategic alternatives. http://www.streetinsider.com/Globe+Newswire/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html Mon, 12 Jan 2026 07:00:00 -0500 A.06822034 LYRA O.04855546 O.20026344 http://www.streetinsider.com/Globe+Newswire/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html <p>WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis (CRS). The Company also announced a workforce reduction impacting its remaining 28 employees and other cost-saving actions to preserve capital. Maria Palasis, Ph.D., Chief Executive Officer, President and Chair of the Board, and Mr. Jason Cavalier, Chief Financial Officer and Treasurer, are each being retained as consultants to support the Company’s pursuit of strategic alternatives. http://www.streetinsider.com/Globe+Newswire/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html Mon, 12 Jan 2026 07:00:00 -0500 A.06822034 LYRA O.04855546 O.20026344 http://www.streetinsider.com/Globe+Newswire/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html <p>WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis (CRS). The Company also announced a workforce reduction impacting its remaining 28 employees and other cost-saving actions to preserve capital. Maria Palasis, Ph.D., Chief Executive Officer, President and Chair of the Board, and Mr. Jason Cavalier, Chief Financial Officer and Treasurer, are each being retained as consultants to support the Company’s pursuit of strategic alternatives. http://www.streetinsider.com/Globe+Newswire/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html Mon, 12 Jan 2026 07:00:00 -0500 A.06822034 LYRA O.04855546 O.20026344 http://www.streetinsider.com/Globe+Newswire/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html <p>WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis (CRS). The Company also announced a workforce reduction impacting its remaining 28 employees and other cost-saving actions to preserve capital. Maria Palasis, Ph.D., Chief Executive Officer, President and Chair of the Board, and Mr. Jason Cavalier, Chief Financial Officer and Treasurer, are each being retained as consultants to support the Company’s pursuit of strategic alternatives. http://www.streetinsider.com/Globe+Newswire/Lyra+Therapeutics+Provides+Corporate+Update/25833903.html Mon, 12 Jan 2026 07:00:00 -0500 A.06822034 LYRA O.04855546 O.20026344 http://www.streetinsider.com/Trading+Halts/Lyra+Therapeutics+%28LYRA%29+Halted%2C+News+Pending/25833774.html <p>Lyra Therapeutics (NASDAQ: LYRA) Halted, News Pending<br /> </p> http://www.streetinsider.com/Trading+Halts/Lyra+Therapeutics+%28LYRA%29+Halted%2C+News+Pending/25833774.html Mon, 12 Jan 2026 06:56:12 -0500 LYRA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Jan+06++Filed+by%3A+Cavalier+Jason/25827120.html si-local-file:///var/storage/secattach/20260108/25827120.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Jan+06++Filed+by%3A+Cavalier+Jason/25827120.html Thu, 08 Jan 2026 16:31:00 -0500 LYRA O.04855546 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Jan+06++Filed+by%3A+Cavalier+Jason/25827120.html si-local-file:///var/storage/secattach/20260108/25827120.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Jan+06++Filed+by%3A+Cavalier+Jason/25827120.html Thu, 08 Jan 2026 16:31:00 -0500 LYRA O.04855546 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Jan+06++Filed+by%3A+Palasis+Maria/25827111.html si-local-file:///var/storage/secattach/20260108/25827111.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Lyra+Therapeutics%2C+Inc.+++For%3A+Jan+06++Filed+by%3A+Palasis+Maria/25827111.html Thu, 08 Jan 2026 16:30:00 -0500 LYRA O.04855546